Focusing on death, which is common to end-of-life care and to euthanasia, is 'a reductionist philosophy that does not reflect clinical reality' . [3] Euthanasia is an active intervention intending to cause the person's death. Palliative care advises that the decision to withhold or withdraw treatment should only be taken after careful consideration by the care team and discussion with the patient (if competent) and the family. Withholding or withdrawing treatment is a sound clinical decision under these circumstances. The statement that the doctor 'legally has the eventual intention to kill the patient' [1] highlights the disconnect between the legal and medical professions on this point, and lack of understanding of clinical reality.
It is a misconception that 'prescribing a potentially fatal palliative dose of medication' [1] is part of medical practice, in particular palliative care. Responsible prescribing of medicine by doctors is reinforced in palliative medicine training, where doctors use sedatives and analgesics, titrating the dose to the patient's response so that the symptoms are controlled without threatening the patient's life. This misconception stems from the 'Doctrine of Double Effect' first described by Thomas Aquinas in the 13th century. Advances in medical knowledge and skill enable doctors to provide quality care without shortening life. Palliative care integrated into cancer care can increase life expectancy. [4] That using opioids or sedatives may shorten life is a myth; 'there is no evidence that the use of opioids or sedatives in palliative care requires the doctrine of double effect as a defence' , and 'although the doctrine is a valid ethical device, it is, for the most part, irrelevant to symptom control at the end of life. To exaggerate its involvement perpetuates a myth that satisfactory symptom control at the end of life is inevitably associated with hastening death. The result can be reluctance to use medication to secure comfort and failure to provide adequate relief to a deeply vulnerable group of patients. ' [5] The Hospice Palliative Care Association of South Africa urges doctors to improve their knowledge and skills in palliative care and pain management, and to refer patients to hospice, or to a palliative care or pain service if they lack the knowledge and skills to address their patient's suffering. Legal and ethics specialists must also update their understanding of palliative care and not perpetuate misconceptions that deprive patients of quality palliative care.
Liz Gwyther
Hospice Palliative Care Association of South Africa liz@hpca.co.za
Prof. McQuoid-Mason responds:
Gwyther's 'great concern' about the fact that two of the four elements necessary for a charge of murder may be satisfied is understandable, but unfounded. The law is clear -unless all four elements are satisfied there is no question of a crime or a civil wrong being perpetrated (see my example in 'Definition of euthanasia' above, concerning surgeons in the operating theatre).
I do not understand the statement that 'Such statements influence professional and public perceptions and create barriers to patient and family access to quality end-of-life care that focuses on relief of suffering and improving quality of life. ' Surely doctors explain to patients and their families that when treatment is withheld or withdrawn in cases of futility, it will hasten the patient's death and not prolong their dying? The doctors know that their act or omission will allow the underlying condition to cause death, but that they are protected by the law because their conduct is regarded as lawful; they may have what the law calls 'eventual intention' , but their conduct is not unlawful. This is because the law recognises that, in Gwyther's words, 'When treatment is futile, is refused or has no benefit, it should not be given just because treatment is available. ' There is no disconnect between the law and medicine on this point, as the law regards such conduct as lawful.
I stand corrected if it is a 'misconception' that the drugs used in palliative may reduce a patient's life expectancy, and in Gwyther's words, that 'symptoms are controlled without threatening the patient's life' . However, the principle regarding the hastening death might apply in other situations -unless such treatment is also no longer practised. Presumably, in the past, when certain drugs did reduce a patient's life expectancy this was fully explained to patients (and to their families) to ensure that such conduct was lawful.
I agree with Gwyther's statement that 'Legal and ethics specialists must also update their understanding of palliative care and not perpetuate misconceptions that deprive patients of quality palliative care. ' I also agree with the statement by Mason and McCall Smith that prompted me to write the article and is quoted at the end: 'When, however, a treatment is discontinued solely by reason of its futility, there is nothing to be lost -and much to be gained by intellectual honesty -in attributing death, correctly, to "Lawful withdrawal of life support systems which were necessitated by [the disease]". ' 
WHIDMT: Rossouw and Howard blatantly miss the point
To the Editor: Rossouw and Howard's response [1] to my article [2] confirms that it is they and not I who miss the point. My key focus [2] was not whether the Women's Health Initiative Dietary Modification Trial (WHIDMT) supports the use of carbohydrate-restricted diets. Nor did my key points focus 'on subgroup findings rather than the robust overall findings' of the study. By introducing these arguments, Rossouw and Howard [1] neatly sidestep the single most important question I raised.
I wished to understand why these authors have yet to communicate the sole significant finding of the WHIDMT, which is that women with established heart disease at the start of the trial fared worse if they changed to the low-fat 'prudent' diet than did those equally ill women who continued to eat a supposedly unhealthy diet. I also showed that the key finding in their Fig. 3 [3] is unintelligible because an essential line of text is missing, and furthermore that no reference is made to Fig. 3 in their response. [1] Instead they dismiss the only significant finding in their study as 'likely to be a chance finding' because 'there is no biologic basis for expecting a different outcome in this [ill] subgroup, as shown in cholesterol-lowering trials of women with prior disease' . [1] An inconvenient outcome is therefore ignored because of their certainty that this adverse result has no (currently known) biological basis.
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There are a number of reasons why this explanation is scientifically unacceptable.
First, the meta-analysis of the 'cholesterol-lowering trials' Rossouw and Howard cite [4] was published in 2012, 6 years after their paper [3] was published in 2006. Second, 'cholesterol-lowering trials' use medications, not diet, to lower blood cholesterol concentrations and hence provide an invalid comparison. Their inability to find a single study showing that dietaryinduced cholesterol lowering improves long-term outcomes is the conclusive admission by these experts that no such evidence exists.
Third, the meta-analysis that Rossouw and Howard cite [4] has been subject to independent re-analysis. [5] The new conclusion is that drug-induced cholesterol lowering in a population at low risk of heart disease, as was the WHIDMT cohort, produced 'no significant effect on overall mortality' , whereas '140 low risk persons would need to be treated with statins for 5 years to prevent one major coronary event or stroke [but] without any reduction in all-cause mortality' . [5] The finding that drug-induced cholesterol lowering provides a marginal benefit to only 1 of 140 treated subjects cannot support their argument that any negative outcomes caused by dietary-induced cholesterol lowering can safely be ignored because they are not biologically plausible. [1] It is important to note that the WHI prudent diet reduced the mean blood low-density lipoprotein cholesterol concentration by just 0.18 mmol/l at 3 years, [3] proving that the most expensive low-fat dietary intervention yet undertaken was essentially ineffective in reversing hypercholesterolaemia.
Fourth, they make no reference to the Estrogenic Replacement and Atherosclerosis (ERA) Trial, [6] which found that coronary atherosclerosis progressed significantly more rapidly over a 3-year period in postmenopausal women eating the equivalent of the WHIDMT lowfat prudent diet than it did in those eating a diet high in saturated fats and low in carbohydrates and polyunsaturated fats.
Rossouw and Howard concede [1] that the WHIDMT was not designed as a trial of the diet-heart hypothesis. This is obvious from the experimental design in which the intervention group also received an 'intensive behavioural modification program' comprising 18 group sessions in the first year followed by quarterly maintenance sessions for the next 7 years. The control group received only a copy of Dietary Guidelines for Americans. This renders mute any conclusions that any positive outcomes can be ascribed purely to dietary change. Yet they are not discouraged from continuing to conclude that 'the lower fat diet ... led to less weight gain, improved insulin resistance (at 1 year), and no increased risk of diabetes risk compared with the control diet' . [1] But once more Rossouw and Howard are economical with the truth, because at the finish of the 8-year trial, there were no biologically important differences between groups in body weight (~500 g) (Fig. 2 [7] ), in blood glucose or insulin concentrations, or in other measures of insulin resistance including homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI) (Table 2 [8] ). In fact, so disappointing were these findings that the authors were forced to conclude not that the dietary intervention produced positive outcomes, but that there were 'no significant adverse effects' (my italics) on insulin sensitivity, [8] a quite different conclusion from that which they aim to project in their letter. [1] Similarly, the only 'robust' conclusion of the total study was that a 'low fat dietary pattern ... showed no evidence of reducing diabetes risk after 8.1 years' . [9] In fact, as early as within the first year of the trial, glucose control worsened significantly in those postmenopausal women with type 2 diabetes mellitus who reduced their fat intake on the high-carbohydrate prudent diet (Table 4 [8] ). Eight-year follow-up data have yet to be reported. Now is perhaps the time for its two senior authors finally to concede that the WHIDMT proved that a low-fat diet with or without an 'intensive behavioural modification program' is likely to be detrimental to the health of postmenopausal women with established heart disease or type 2 diabetes, and that mechanisms well described in the literature can readily explain these adverse outcomes.
These findings have important implications for dietary advice to women with either established coronary artery disease or type 2 diabetes mellitus, and could have wider connotations. 
T D Noakes

